2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12D.03 Characterization of HER2Alterations in 23,321 NSCLC Cases and Real-World Therapeutic Pattern in Chinese HER2-Mutant NSCLC the CHAPTER Study

EP.12D.03 Characterization of HER2Alterations in 23,321 NSCLC Cases and Real-World Therapeutic Pattern in Chinese HER2-Mutant NSCLC the CHAPTER Study

Back to course

Pdf Summary

The study examined the prevalence and treatment effectiveness of ERBB2 mutations in non-small cell lung cancer (NSCLC) among Chinese patients. Using extensive genomic data from the LANDSCAPE project and real-world clinical data from 23,321 NSCLC tissue samples, ERBB2 alterations were found in 5% of the cases, with specific mutations comprising 3.8%. Detailed analyses included genes like EGFR, MET, and others, to ascertain co-occurring ERBB2 mutations.<br /><br />A cohort of 309 patients from Chinese hospitals revealed diverse treatment responses. First-line therapies showed varying outcomes; EGFR-TKIs achieved the highest real-world progression-free survival (rwPFS) of 10 months, while chemotherapy without additional agents recorded 6.5 months. In the second-line setting, trastuzumab deruxtecan (T-DXd) excelled with a rwPFS of 10 months, significantly better than other regimens.<br /><br />The study emphasizes that comprehensive molecular profiling can refine therapeutic choices and improve outcomes for ERBB2-mutated NSCLC patients. T-DXd demonstrates superior efficacy over other HER2-targeted treatments, suggesting it as a promising option for Chinese patients. The research highlights the need for optimized treatment stratagems in the Chinese context, as the country has not yet approved some effective therapies like Enhertu. This suggests that understanding regional and genetic particularities can enhance the clinical strategies for managing lung cancer with HER2 alterations.

Asset Subtitle

Bo Jia

Meta Tag

Speaker Bo Jia

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

ERBB2 mutations

non-small cell lung cancer

NSCLC

Chinese patients

genomic data

LANDSCAPE project

EGFR-TKIs

trastuzumab deruxtecan

molecular profiling

HER2-targeted treatments